Company | Cencora, Inc. | Ticker | COR (NYSE) |
Reporting Period | FY2026 Q3 (quarter ended June 30, 2026) | Earnings Date | August 5, 2026 — 8:30 AM ET |
Prepared | August 4, 2026 | Last Earnings | May 6, 2026 (FY2026 Q2) |
Key Takeaway: The setup into COR's FY2026 Q3 print is modestly constructive — consensus has been revised up since the Q2 miss, the bar is not stretched, and the biggest swing factor is whether U.S. Healthcare Solutions operating income can sustain high-single-digit growth as OneOncology accretion ramps and the oncology customer lap approaches in Q4.
Bar: Consensus U.S. Healthcare Solutions operating income for Q3 stands at ~$940M, implying roughly 13% YoY growth — a step-down from Q2's 5.6% reported growth but consistent with management's full-year 14–16% guidance range, which is back-half weighted. The revenue bar (~$84.4B) is modest given the full-year guide was already cut to 4–6% growth after Q2's biosimilar and GLP-1 headwinds, so a revenue beat is achievable but low-margin and unlikely to move the stock.
Guidance/Tone: Management entered Q3 with a confident tone on operating income durability, explicitly guiding Q3 adjusted diluted EPS growth in the high single digits and flagging that net interest expense would remain at ~$140M before stepping down modestly in Q4. The EPS guide raise at Q2 was largely mechanical (MWI depreciation suspension, lower interest, buyback), but management's reiteration of the long-term 7–10% organic operating income growth framework signals no fundamental deterioration.
Estimate Trajectory: Consensus adjusted diluted EPS for Q3 has drifted from $3.84 (as of May 13, 2026) to $3.92 currently — a modest ~2% upward revision post-Q2, consistent with the MWI accounting benefit and buyback tailwind. Full-year FY2026 EPS consensus of ~$17.79 sits near the midpoint of management's $17.65–$17.90 guidance range, leaving limited room for a guidance raise unless underlying operating income outperforms.
Stock Setup: COR has recovered from its post-Q2 selloff (from ~$372 pre-Q2 to a low near $252 on May 6) and now trades around $306, implying a NTM P/E of ~15.8x — below its 6-month-ago multiple of ~19.8x, suggesting the stock has de-rated meaningfully and the bar for a positive reaction is lower. The stock is up ~21% from its post-Q2 low but still down ~15.7% over the past six months, meaning sentiment is recovering but not euphoric.
Wildcard: The single biggest wildcard is the pace of Part B biosimilar conversions in oncology and retina — management characterized these as incrementally beneficial to practices and Cencora (unlike Part D conversions which bypass the wholesaler), and any commentary on accelerating Part B biosimilar uptake through OneOncology and RCA could meaningfully re-rate the operating income growth outlook. Conversely, any further GLP-1 volume disappointment or commentary on the large mail-order customer's conversion pace could weigh on the revenue line again.
Key Takeaway: The operating income bar is achievable but not easy — U.S. Healthcare Solutions OI consensus of ~$940M implies a meaningful step-up from Q2's $998M actuals on a sequential basis, but YoY comparisons are favorable. Revenue is a low-bar metric given the already-cut guidance; the real swing factor is whether adjusted operating income growth tracks the 12–14% full-year guide.
KPI | Last Quarter Actual (FY2026 Q2) | Prior Year Period Actual (FY2025 Q3) | Q3 Consensus Estimate | YoY Change | Guidance | Consensus vs. Guidance |
Revenue ($B) | $78.4B | $80.7B | $84.4B | +4.6% YoY | FY26: +4–6% growth (implies ~$333–$340B full year) | Within range |
Adj. Diluted EPS ($) | $4.75 | $4.00 | $3.92 | -2.0% YoY | Q3 guide: high-single-digit growth; FY26: $17.65–$17.90 | ~-2% vs. Q3 implied midpoint; within FY range |
U.S. Healthcare Solutions Operating Income ($M) | $998.3M | $833.7M | $940.2M | +12.8% YoY | FY26: +14–16% growth | Within range |
Total Adj. Operating Income ($M) | $1,263.4M | $1,058.3M | $1,196.9M | +13.1% YoY | FY26: +12–14% growth | Within range |
Free Cash Flow ($M) | $1,169.7M | -$73.9M | $2,503.6M | N/M (prior year negative) | FY26: ~$3.0B | On track |
Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of August 4, 2026. Prior year actuals and last quarter actuals from Visible Alpha reported figures. FY2026 Q3 = quarter ending June 30, 2026 (COR fiscal calendar: FY ends September 30).
KPI 1: Adjusted Diluted EPS | KPI 2: U.S. Healthcare Solutions Operating Income
Quarter | KPI | Reported | Consensus | Surprise % | Result |
FY2026 Q2 (Mar 2026) | Adj. EPS | $4.75 | $4.80 | -1.0% | Miss |
FY2026 Q2 (Mar 2026) | U.S. HCS OI | $998.3M | $1,044.6M | -4.4% | Miss |
FY2026 Q1 (Dec 2025) | Adj. EPS | $4.08 | $4.07 | +0.2% | Beat |
FY2026 Q1 (Dec 2025) | U.S. HCS OI | $831.3M | $795.0M | +4.6% | Beat |
FY2025 Q4 (Sep 2025) | Adj. EPS | $3.84 | $3.77 | +1.9% | Beat |
FY2025 Q4 (Sep 2025) | U.S. HCS OI | $817.9M | $841.6M | -2.8% | Miss |
FY2025 Q3 (Jun 2025) | Adj. EPS | $4.00 | $3.84 | +4.2% | Beat |
FY2025 Q3 (Jun 2025) | U.S. HCS OI | $833.7M | $850.7M | -2.0% | Miss |
FY2025 Q2 (Mar 2025) | Adj. EPS | $4.42 | $4.09 | +8.1% | Beat |
FY2025 Q2 (Mar 2025) | U.S. HCS OI | $944.9M | $931.1M | +1.5% | Beat |
FY2025 Q1 (Dec 2024) | Adj. EPS | $3.73 | $3.50 | +6.6% | Beat |
FY2025 Q1 (Dec 2024) | U.S. HCS OI | $686.9M | $724.6M | -5.2% | Miss |
FY2024 Q4 (Sep 2024) | Adj. EPS | $3.34 | $3.23 | +3.4% | Beat |
FY2024 Q4 (Sep 2024) | U.S. HCS OI | $634.1M | $671.4M | -5.6% | Miss |
FY2024 Q3 (Jun 2024) | Adj. EPS | $3.34 | $3.21 | +4.0% | Beat |
FY2024 Q3 (Jun 2024) | U.S. HCS OI | $635.5M | $683.8M | -7.1% | Miss |
Key Takeaway: Estimates have drifted modestly higher since the Q2 print, tracking the MWI accounting benefit and buyback tailwind rather than any fundamental operating income upgrade. The gap between consensus and guidance midpoints is narrow, suggesting limited room for a guidance raise unless Q3 operating income materially outperforms.
KPI (Period) | Estimate (May 13, 2026 — 5 days post Q2) | Current Consensus (Aug 4, 2026) | Estimate Δ (%) | Initial Guidance (May 6 Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
Adj. EPS — FY2026 Q3 | $4.38 | $3.92 | -10.5% | High single-digit growth (implied ~$4.30–$4.40) | Unchanged | — | ~-10% below implied midpoint |
Adj. EPS — FY2026 (Full Year) | $17.79 | $17.79 | 0.0% | $17.65 – $17.90 | Unchanged | — | At midpoint |
Revenue — FY2026 Q3 | $84.8B | $84.4B | -0.5% | FY26: +4–6% growth | Unchanged | — | Within range |
Revenue — FY2026 (Full Year) | $337.8B | $337.8B | 0.0% | +4–6% growth (~$333–$340B) | Unchanged | — | At midpoint |
U.S. HCS OI — FY2026 Q3 | $949.0M | $940.2M | -0.9% | FY26: +14–16% growth | Unchanged | — | Within range |
U.S. HCS OI — FY2026 (Full Year) | $3,778.7M | $3,772.7M | -0.2% | +14–16% growth (~$3.76–$3.83B) | Unchanged | — | At low end of range |
Adj. EPS — FY2027 (Full Year) | $19.81 | $19.83 | +0.1% | No FY2027 guidance provided | — | — | N/A |
Source: Visible Alpha Consensus and Actuals Data. Baseline as of May 13, 2026 (5 trading days post Q2 earnings). The notable divergence in Q3 EPS consensus ($3.92) vs. management's implied high-single-digit growth guide (~$4.30–$4.40) warrants attention — if management's Q3 cadence commentary was taken literally, consensus may be materially below the implied bar, creating potential for a positive EPS surprise even on modest operating income performance.
Key Takeaway: COR's post-Q2 recovery (+21% from the May 6 low of $252.74 to $306.28 on August 4) has been driven by multiple re-expansion from deeply oversold levels, not estimate upgrades. The stock has meaningfully underperformed IHI (iShares U.S. Medical Devices ETF, used as the healthcare sector proxy) and the S&P 500 over the six-month window, reflecting the revenue guide cut and sentiment reset. The NTM P/E has compressed from ~19.8x six months ago to ~15.8x today, suggesting the de-rating is largely complete but a re-rating requires evidence of operating income durability.
Sector ETF: IHI (iShares U.S. Medical Devices ETF) is used as the healthcare sector proxy. Note: COR is a pharmaceutical distributor, not a medical device company — IHI is the closest available broad healthcare ETF for indexing purposes. A more precise peer would be a pharmaceutical distribution index, but no single-ticker ETF exists for that sub-sector.
Date | COR (Indexed) | IHI (Indexed) | SPY (Indexed) |
May 6, 2026 (Base) | 100.0 | 100.0 | 100.0 |
May 29, 2026 | 106.5 | 98.5 | 103.1 |
Jun 12, 2026 | 111.4 | 99.9 | 101.0 |
Jun 30, 2026 | 111.9 | 99.4 | 101.8 |
Jul 8, 2026 | 122.5 | 103.1 | 101.6 |
Jul 28, 2026 | 126.4 | 106.0 | 101.0 |
Aug 4, 2026 | 121.1 | 108.9 | 105.1 |
Key Events Since May 6, 2026:
Source: Stock Price Data (Yahoo Finance). Indexed to 100 at May 6, 2026 close of $252.74 for COR, $49.71 for IHI, $733.83 for SPY.
Stock Performance Decomposition (NTM EV/EBITDA):
Horizon | Price Change | NTM EV/EBITDA (Start) | NTM EV/EBITDA (Current) | Multiple Change | Driver |
1 Month | +2.6% | 11.6x | 12.0x | +3.6% | Multiple-led recovery |
3 Months | +0.9% | 11.5x | 12.0x | +4.5% | Multiple expansion offsetting earnings headwind |
6 Months | -15.7% | 13.4x | 12.0x | -9.9% | Multiple contraction + earnings miss drove decline |
12 Months | +6.2% | 11.8x | 12.0x | +2.4% | Modest multiple expansion; earnings growth the primary driver |
Source: Stock Performance Decomposition Data (Visible Alpha / Yahoo Finance). The 6-month window captures the full impact of the Q2 miss and subsequent recovery. The stock's de-rating from ~13.4x to ~12.0x NTM EV/EBITDA over six months reflects the revenue guide cut and sentiment reset; the current 12.0x is below the 5-year average, suggesting the stock is not expensive heading into Q3.
Key Takeaway: The most important post-Q2 development is the CHRO leadership transition (operationally immaterial) and the two clustered director open-market purchases in late May/June — the latter is the most meaningful signal, suggesting board-level conviction in the stock at post-selloff levels. No guidance changes, no M&A updates, and no regulatory developments have occurred since May 6.
Key Takeaway: Two clustered open-market purchases by Director Dermot Durcan (8,000 shares total, ~$2.15M) and one purchase by Director Lauren Tyler (550 shares, ~$149K) in the weeks following the Q2 selloff are a notable constructive signal. No insider sales have been filed. The buying occurred at prices well below pre-Q2 levels (~$267–$271 vs. ~$372 pre-earnings), suggesting board-level conviction that the selloff was overdone.
Name | Title | Transaction Type | Shares | Est. Value | Transaction Date | Filing Date | Note |
Dermot Mark Durcan | Director | Open Market Buy | 4,000 | ~$1.07M | May 28, 2026 | May 28, 2026 | Discretionary; no 10b5-1 plan. First post-Q2 insider buy. Holdings: 27,767 shares post-transaction. |
Dermot Mark Durcan | Director | Open Market Buy | 4,000 | ~$1.08M | Jun 18, 2026 | Jun 22, 2026 | Discretionary; no 10b5-1 plan. Second consecutive buy; holdings: 31,767 shares post-transaction. |
Lauren M. Tyler | Director | Open Market Buy | 550 | ~$149K | Jun 22, 2026 | Jun 24, 2026 | Discretionary; no 10b5-1 plan. Holdings: 4,359 shares post-transaction. |
Source: SEC Form 4 Filings (Insider Transaction Data). All transactions are open-market purchases (Form 4 code P), classified as Acquisitions (Type A). No insider sales or 10b5-1 plan initiations have been filed in the period since the Q2 earnings date. No management-level (CEO, CFO, EVP) transactions were filed in this window.
Key Takeaway: Peer commentary from the past 60 days that covers the calendar Q2 2026 period (April–June 2026, which aligns with COR's FY2026 Q3) provides a broadly constructive read-through on specialty pharmaceutical demand, oncology utilization, and GLP-1 volumes. The most relevant signals come from pharmaceutical manufacturers (NVO, BMY, ABBV) whose products COR distributes, not from distribution peers.
Conventional distribution peers McKesson (MCK) and Cardinal Health (CAH) are excluded from this read-through section for the following reasons:
The read-throughs below are drawn exclusively from pharmaceutical manufacturers and healthcare companies that reported Q2 calendar 2026 results (covering April–June 2026) within the past 60 days, with direct relevance to COR's distribution volumes, product mix, or end-market demand.
Period Covered: Calendar Q2 2026 (April–June 2026) = COR FY2026 Q3.
Key Commentary:
COR Read-Through: Positive. NVO's stronger-than-expected U.S. GLP-1 demand in Q2 calendar 2026 directly implies higher distribution volumes for COR in its FY2026 Q3 (the same period). COR flagged slower-than-expected GLP-1 growth as a key revenue headwind at Q2 earnings (May 6); NVO's Q2 data suggests the GLP-1 volume environment may have improved sequentially, which could partially offset the headwind COR guided to. The oral-to-injectable mix shift (Wegovy pill gaining share) is also relevant — COR distributes both forms, but the pill format may have different margin dynamics.
Limitations: NVO's revenue growth reflects manufacturer-level demand, not necessarily wholesaler-level volumes. COR's GLP-1 revenue headwind was partly driven by IRA/WAC price reductions and mix, not just volume. NVO's improved guidance does not directly translate to a COR revenue upgrade.
Period Covered: Calendar Q2 2026 (April–June 2026) = COR FY2026 Q3.
Key Commentary:
COR Read-Through: Positive for specialty/oncology volumes. BMY's strong oncology portfolio performance in Q2 calendar 2026 is a direct read-through for COR's specialty pharmaceutical distribution volumes in FY2026 Q3. The wholesale inventory build noted for Opdivo/Qvantig is particularly relevant — it suggests distributors (including COR) were building inventory in Q2 calendar 2026, which is a positive volume signal. Eliquis' 21% growth implies continued high-volume distribution activity. The raised full-year guidance from BMY is a constructive signal for the pharmaceutical demand environment COR operates in.
Limitations: BMY's inventory build commentary is product-specific (Opdivo/Qvantig) and may not generalize across COR's full portfolio. BMY's summer demand moderation comment for Breyanzi is a cell therapy product with different distribution dynamics than traditional pharmaceuticals. BMY has no GLP-1 exposure, limiting read-through on that specific headwind for COR.
Period Covered: Calendar Q2 2026 (April–June 2026) = COR FY2026 Q3.
Key Commentary:
COR Read-Through: Mixed but net positive. ABBV's strong immunology and neuroscience volumes in Q2 calendar 2026 are a positive read-through for COR's specialty distribution volumes. The Humira biosimilar erosion (-35.9%) is a known headwind that COR has been managing, but the growth of Skyrizi and Rinvoq more than offsets it in volume terms. The Imbruvica decline (-29.4%) is relevant to COR's oncology distribution mix. New product approvals (Decnupaz, Tepkinly) represent incremental distribution opportunities for COR's specialty oncology platform. The Apogee acquisition closing in Q3 2026 will add new pipeline products to ABBV's portfolio, creating future distribution opportunities.
Limitations: ABBV's revenue figures are manufacturer-level and do not directly translate to COR's distribution margins. The Humira biosimilar dynamic is a known headwind already embedded in COR's guidance. ABBV has no GLP-1 exposure. The Apogee acquisition impact on COR's distribution volumes is not quantifiable at this stage.
Period Covered: Calendar Q2 2026 (April–June 2026) = COR FY2026 Q3.
Key Commentary:
COR Read-Through: Modestly positive. PFE's strong non-COVID portfolio performance in Q2 calendar 2026 (Eliquis, Padcev, Vyndaqel) implies continued high-volume distribution activity for COR. The sharp decline in Paxlovid (-95%) and Comirnaty (-34%) is a known headwind for COR's COVID-related distribution volumes, but these are low-margin products. The raised full-year revenue guidance from PFE is a constructive signal for the pharmaceutical demand environment.
Limitations: PFE's COVID product declines are already embedded in COR's guidance. PFE's cost-cutting focus does not directly impact COR's distribution economics. PFE has no GLP-1 exposure.
Peer | Report Date | Period Covered | Key COR Read-Through | Signal |
Novo Nordisk (NVO) | Aug 4, 2026 | Cal Q2 2026 = COR FY26 Q3 | Higher U.S. GLP-1 demand; Wegovy pill >5M Rx; improved full-year guidance | Positive |
Bristol-Myers Squibb (BMY) | Jul 30, 2026 | Cal Q2 2026 = COR FY26 Q3 | Oncology portfolio +14%; wholesale inventory build for Opdivo/Qvantig; Eliquis +21% | Positive |
AbbVie (ABBV) | Jul 31, 2026 | Cal Q2 2026 = COR FY26 Q3 | Immunology +15%; Skyrizi/Rinvoq strong; Humira biosimilar erosion ongoing; new oncology approvals | Mixed / Net Positive |
Pfizer (PFE) | Aug 4, 2026 | Cal Q2 2026 = COR FY26 Q3 | Non-COVID portfolio strong; Paxlovid/Comirnaty declines known; raised revenue guidance | Modestly Positive |
McKesson (MCK) | N/A — Excluded | MCK FY27 Q1 (Apr–Jun 2026) not yet reported | No qualifying commentary for COR's current reporting period | Excluded |
Cardinal Health (CAH) | N/A — Excluded | CAH FY26 Q4 (Apr–Jun 2026) reports Aug 11, 2026 | No qualifying commentary for COR's current reporting period | Excluded |
Overall Read-Through Assessment: The aggregate peer commentary from pharmaceutical manufacturers covering calendar Q2 2026 is net positive for COR's FY2026 Q3 setup. GLP-1 demand appears to have improved sequentially (NVO), specialty/oncology volumes were robust (BMY, ABBV), and the broader pharmaceutical demand environment was healthy (PFE). The key risk — biosimilar conversion pace at the large mail-order customer — is not directly observable from manufacturer-level data, as it is a COR-specific customer dynamic. The absence of MCK and CAH commentary for the current period means the most direct distribution-level read-through will only be available after COR's own print.
Disclosure Note: All peer commentary cited above was released within the past 60 days (June 5 – August 4, 2026) and covers the calendar Q2 2026 period (April–June 2026), which directly aligns with COR's FY2026 Q3 reporting period. No commentary from prior quarters (e.g., MCK's FY2026 Q4 covering January–March 2026) has been included, consistent with the user's instruction to include only commentary about the current reporting quarter.